Serum big endothelin-1 levels in female patients with breast cancer

Yıldırım, Yeşim; Günel, Nazan; Coşkun, Uğur; Sancak, Banu; Bukan, Neslihan; Aslan, Sabahattin; Çetin, Abdullah

doi:10.1016/j.intimp.2008.03.023

Cited by 10 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This could be attributed to the removal of the tumor as well as the effect of the adjuvant therapy itself. These findings are consistent with other researches [21][22][23][24].…”

Section: Discussionsupporting

confidence: 94%

“…This observation was in accordance with other studies [16,21] that stated that there was no correlation between circulating big ET-1 and tumor size, thus the increase in big ET-1 was due to a difference in production and secretion rate of tumors. Besides, the lack of a correlation between CA15.3 and the clinicopathological characteristics was due to cytokines which depend on the neoplasm activity and not on the stage of the disease or the histological type of the tumor [25,[30][31][32].…”

Section: Discussionsupporting

confidence: 93%

“…This could be due to the deregulation of ECE expression or activity affecting the balance between the precursor molecule and its active form [20] or simply due to the presence of the tumor [21]. Serum levels of big ET-1 in all patients significantly decreased after finishing the adjuvant therapy protocol recording normal levels.…”

Section: Discussionmentioning

confidence: 92%

See 2 more Smart Citations

Evaluation of serum big endothelin-1 for the diagnosis and prediction of disease recurrence in breast cancer patients

Na¹,

Mohammad²,

Elkerm³

et al. 2013

J Cancer Res Ther

View full text Add to dashboard Cite

“…This could be attributed to the removal of the tumor as well as the effect of the adjuvant therapy itself. These findings are consistent with other researches [21][22][23][24].…”

Section: Discussionsupporting

confidence: 94%

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Evaluation of serum big endothelin-1 for the diagnosis and prediction of disease recurrence in breast cancer patients

Na¹,

Mohammad²,

Elkerm³

et al. 2013

J Cancer Res Ther

View full text Add to dashboard Cite

“…This is accomplished primarily through the activity of endothelin-converting enzyme-1 (ECE-1). In pathological conditions increased plasma and tissue levels of ET-1 as well as big ET-1 have been measured (Ishibashi et al, 1991; Rubens et al, 2001; Ihling et al, 2004; Masson et al, 2006; Yildirim et al, 2008), and in addition to ET-1, numerous cell types have been reported to secrete big ET-1 (Emori et al, 1989; Sawamura et al, 1989; Odoux et al, 1997). To assess the ability of DH82 cells to secrete big ET-1 in addition to ET-1, cells were cultured in the presence or absence of LPS, and with the addition of increasing concentrations of the endothelin-converting enzyme inhibitor SM-19712.…”

Section: Resultsmentioning

confidence: 99%

Endothelin-1 production by the canine macrophage cell line DH82: Enhanced production in response to microbial challenge

Divino

Chawla

Silva

et al. 2010

Veterinary Immunology and Immunopathology

View full text Add to dashboard Cite

Endothelin-1 (ET-1) is a potent vasoconstrictive peptide which plays an important role in regulating mammalian cardiovascular development and homeostasis. Originally identified as a factor released by vascular endothelial cells, ET-1 is now recognized as a product of numerous cells and tissues with demonstrated involvement in an array of physiological and pathological processes. An area of great interest is the production of ET-1 by mononuclear cells (monocytes and macrophages) and its role in inflammation. We report that the canine macrophage cell line, DH82, constitutively secretes both ET-1 and its biologically inactive precursor big ET-1. The production of both peptides was increased following stimulation with lipopolysaccharide (endotoxin) from gram-negative bacteria. ET-1 production was also increased in response to stimulation with intact and viable gram-positive and gram-negative bacteria. In addition to producing ET-1, DH82 cells express transcripts encoding two receptors for the ET-1 peptide (ET A and ET B receptors) and an enzyme involved in the conversion of big ET-1 to ET-1. The constitutive secretion of ET-1 and the expression of ET A and ET B receptors may be related to the malignant origin of this cell line. Our results are the first report of ET-1 production by a canine cell line and provide the basis for further investigation into the role of ET-1 during infection and inflammation.

show abstract

“…Established prognostic factors [5,8,9] as well as new possible factors, such as the E-cadherin transcriptional repressor Snail or the c-Jun activation domain binding protein-1 (Jab1), are multifunctional signaling proteins that are controversially discussed in the literature [10][11][12]. Despite these ongoing modifications, tumor size in multicentric/multifocal tumors is only assessed by the largest tumor focus and does not reflect the cumulative tumor volume.…”

Section: Introductionmentioning

confidence: 99%

Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified?

Weißenbacher¹,

Zschage²,

Janni

et al. 2010

Breast Cancer Res Treat

137

View full text Add to dashboard Cite

For classification of breast cancer (BC), tumor-node-metastasis (TNM) staging has been considered state of the art for more than 50 years. The T category is well defined, and in multicentric and multifocal tumors, tumor size is assessed by the largest tumor focus. The aim of this study was to compare multicentric/multifocal tumor spread in breast cancer with unifocal disease and to evaluate the diagnostic relevance of multifocality. A retrospective analysis was performed on survival related events in a series of 5,691 breast cancer patients between 1963 and 2007. By matched-pair analysis, patients were entered into two comparable groups of 288 patients after categorizing them as having multifocal/multicentric or unifocal breast cancers. Matching criteria were tumor size, grading, and hormone receptor status, which were equally distributed between both groups (P = 1.000 each). Disease free survival and the occurrence of relapse or of metastatic disease were evaluated. Cox's regression analysis was used for multivariate analysis. In the unifocal group, the mean breast cancer-specific survival time was 221.6 months as opposed to 203.3 months in the multicentric/multifocal group (P < 0.001, log-rank test). The occurrence of local relapse and distant metastasis was significantly increased in the multifocal group in comparison to the unifocal equivalent group (P < 0.001 and P < 0.003, respectively). Cox regression analysis for multivariate analyses demonstrated focality and centricity to be highly significant predictors for reduced overall survival (P = 0.016), local relapse (P = 0.001) and distant metastasis (P = 0.038). Tumor size, histopathological grading, hormone receptor status, and staging of lymph nodes are well-established prognostic parameters. Additionally, the number of foci should be considered as an independent prognostic parameter, which is currently not reflected in the TNM classification. We conclude that multicentric/multifocal BC is an independent BC risk factor and should be included in the risk assessment by re-evaluating the current TNM classification of the UICC.

show abstract

Serum big endothelin-1 levels in female patients with breast cancer

Cited by 10 publications

References 19 publications

Evaluation of serum big endothelin-1 for the diagnosis and prediction of disease recurrence in breast cancer patients

Evaluation of serum big endothelin-1 for the diagnosis and prediction of disease recurrence in breast cancer patients

Endothelin-1 production by the canine macrophage cell line DH82: Enhanced production in response to microbial challenge

Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified?

Contact Info

Product

Resources

About